---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107118"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:12:14.435556+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MaxCyte reports preliminary Q3 2025 revenue of $6.8M, down 16% YoY; reiterates FY2025 guidance

## Summary
- Total revenue $6.8M, core revenue $6.4M (-21% YoY); adds three new SPL clients including Moonlight Bio.
- Gross margin 77%; non-GAAP adjusted gross margin 81% (excl. SPL program revenue and inventory reserves).
- Rescheduled Q3 earnings call to Nov 12, 2025 due to impairment testing of goodwill and long-lived assets; no prior quarter impact.
- Cash and investments $158.0M at Sept 30, 2025; expects year-end cash $152-155M reflecting restructuring costs.
- Reiterates FY2025 core revenue guidance: flat to -10% vs 2024; SPL program-related revenue ~$5M.

## SEC filing metadata
- accession: 0001104659-25-107118
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000110465925107118/0001104659-25-107118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000110465925107118/mxct-20251105x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107118
- JSON: https://secwatch.observer/filing/0001104659-25-107118.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.